Psych MEQs / SAQs · Child and adolescent psychiatry — neurodevelopmental
Autism spectrum disorder — assessment to irritability management (MEQ)
FRANZCP-style MEQ on ASD criteria, differentials, early intervention evidence, irritability pharmacotherapy with monitoring, and transition/capacity framing.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Criteria and severity. ASD requires persistent deficits in all three social-communication domains (reciprocity; nonverbal communicative behaviour; relationships) and at least two of four RRB domains (stereotypies/repetitive speech or object use; insistence on sameness; restricted interests; sensory hyper/hyporeactivity), early developmental onset, impairment, and not better explained by intellectual disability alone. Rate severity separately for social communication and RRBs as Level 1–3 support need.[1]
(ii) Differentials. ADHD: inattention/impulsivity core; social interest often present; high co-occurrence. ID alone: social skills roughly match developmental level; ASD requires deficit beyond developmental expectation. Social anxiety: fear of scrutiny with skills often intact when comfortable. SCD: social language deficits without RRBs. This child has RRBs (timetables, sameness distress) → ASD not SCD.[1]
(iii) Non-drug package. Educational adjustments, speech/OT, structured behavioural supports, parent training, and early developmental intervention. Name ESDM (Dawson RCT) and PACT (Green parent-mediated RCT); Bearss parent training for disruptive behaviour outperforms education alone.[4][5][6]
(iv) Irritability medicines. After functional analysis, medical pain screen and behavioural optimisation, severe ongoing aggression/self-injury may justify risperidone (RUPP/McCracken: low weight-based start e.g. about 0.25–0.5 mg/day with slow titration; monitor weight, metabolic panel, EPS, prolactin) or aripiprazole (Owen: start commonly 2 mg daily, titrate toward trial effective range; monitor metabolic effects and akathisia). Neither treats core social deficits. Review for dose minimisation once stable.[2][3]
(v) Capacity and transition. Decision-specific capacity with supported decision-making; least restrictive care under local law. From mid-teens plan CAMHS-to-adult transition: written care plan, education/employment, medication review, housing, safeguarding against exploitation, and adult mental health follow-up for comorbidity risk.[1]
Common errors
- Saying any peer problem equals ASD.
- Prescribing antipsychotics for mild meltdowns without behavioural formulation.
- Claiming SSRIs treat core RRBs (citalopram negative trial knowledge helps avoid this).
- Inventing foreign Mental Health Act section numbers.
- Omitting metabolic monitoring for risperidone/aripiprazole. [2][3]
Examiner notes
Full marks need DSM structure with levels, at least three discriminators, named early intervention trials, named drug with start approach and monitoring, and transition/capacity principles. Vague "refer to paeds and start an atypical" fails. [1][2]
References
- [1]Hyman SL, Levy SE, Myers SM; Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics Identification, Evaluation, and Management of Children With Autism Spectrum Disorder Pediatrics, 2020.PMID 31843864
- [2]McCracken JT, McGough J, Shah B, et al.; Research Units on Pediatric Psychopharmacology Autism Network Risperidone in children with autism and serious behavioral problems N Engl J Med, 2002.PMID 12151468
- [3]Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder Pediatrics, 2009.PMID 19948625
- [4]Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model Pediatrics, 2010.PMID 19948568
- [5]Green J, Charman T, McConachie H, et al. Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial Lancet, 2010.PMID 20494434
- [6]Bearss K, Johnson C, Smith T, et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial JAMA, 2015.PMID 25898050